Zentalis reports interim overall‑survival data for azenosertib in biomarker‑selected ovarian cancer
Zentalis Pharmaceuticals presented interim overall‑survival results from the DENALI Part 1b study of its WEE1 inhibitor azenosertib in platinum‑resistant ovarian cancer. Median overall survival was 15.8 months in the Cyclin E1‑positive subgroup and 7.5 months in the Cyclin E1‑negative subgroup. The data were presented at the ESMO Congress and support the biomarker‑driven development path for the drug.
Why it matters
The company says the survival signal in Cyclin E1‑positive patients strengthens the case for accelerated approval and underpins the ongoing DENALI Part 2 and ASPENOVA Phase 3 trials. Zentalis also disclosed $174.6 million in cash, which it expects will fund operations into late 2027, reducing near‑term financing risk.
Key facts
- 1Median overall survival was 15.8 months in the Cyclin E1‑positive subgroup (n=48). stocktitan.net
- 2Median overall survival was 7.5 months in the Cyclin E1‑negative subgroup (n=46). stocktitan.net
- 3The interim analysis used a data cutoff of September 2, 2025. mugglehead.com
- 4DENALI Part 1b enrolled 102 patients with platinum‑resistant ovarian cancer. stocktitan.net
- 5Zentalis held $174.6 million in cash, cash equivalents and marketable securities at June 30, 2026. mugglehead.com
Open questions
- Material 9 reports median overall survival of 15.9 months in Cyclin E1‑positive patients, differing from the 15.8 months reported in material 1.
Summary written by AlphAI AI Desk from 9 of 9 sources. Not investment advice. Figures are as stated by the linked sources.